ABUS
Price
$3.21
Change
-$0.01 (-0.31%)
Updated
Dec 20, 04:59 PM (EDT)
68 days until earnings call
LRMR
Price
$3.99
Change
+$0.01 (+0.25%)
Updated
Dec 20, 04:59 PM (EDT)
81 days until earnings call
Ad is loading...

ABUS vs LRMR

Header iconABUS vs LRMR Comparison
Open Charts ABUS vs LRMRBanner chart's image
Arbutus Biopharma
Price$3.21
Change-$0.01 (-0.31%)
Volume$78.12K
CapitalizationN/A
Larimar Therapeutics
Price$3.99
Change+$0.01 (+0.25%)
Volume$11.65K
CapitalizationN/A
ABUS vs LRMR Comparison Chart
Loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABUS vs. LRMR commentary
Dec 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Hold and LRMR is a Hold.

COMPARISON
Comparison
Dec 21, 2024
Stock price -- (ABUS: $3.21 vs. LRMR: $4.03)
Brand notoriety: ABUS and LRMR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABUS: 323% vs. LRMR: 125%
Market capitalization -- ABUS: $608.27M vs. LRMR: $256.82M
ABUS [@Biotechnology] is valued at $608.27M. LRMR’s [@Biotechnology] market capitalization is $256.82M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 0 FA rating(s) are green whileLRMR’s FA Score has 1 green FA rating(s).

  • ABUS’s FA Score: 0 green, 5 red.
  • LRMR’s FA Score: 1 green, 4 red.
According to our system of comparison, LRMR is a better buy in the long-term than ABUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 4 TA indicator(s) are bullish while LRMR’s TA Score has 4 bullish TA indicator(s).

  • ABUS’s TA Score: 4 bullish, 4 bearish.
  • LRMR’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ABUS is a better buy in the short-term than LRMR.

Price Growth

ABUS (@Biotechnology) experienced а -7.76% price change this week, while LRMR (@Biotechnology) price change was -34.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

ABUS is expected to report earnings on Feb 27, 2025.

LRMR is expected to report earnings on Mar 12, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABUS($608M) has a higher market cap than LRMR($257M). ABUS YTD gains are higher at: 28.400 vs. LRMR (-11.538). LRMR (-73.44M) and ABUS (-75.14M) have comparable annual earnings (EBITDA) . LRMR has more cash in the bank: 204M vs. ABUS (128M). ABUS has less debt than LRMR: ABUS (1.45M) vs LRMR (5.36M). ABUS has higher revenues than LRMR: ABUS (6.74M) vs LRMR (0).
ABUSLRMRABUS / LRMR
Capitalization608M257M237%
EBITDA-75.14M-73.44M102%
Gain YTD28.400-11.538-246%
P/E RatioN/AN/A-
Revenue6.74M0-
Total Cash128M204M63%
Total Debt1.45M5.36M27%
FUNDAMENTALS RATINGS
ABUS vs LRMR: Fundamental Ratings
ABUS
LRMR
OUTLOOK RATING
1..100
852
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
23
Undervalued
PROFIT vs RISK RATING
1..100
64100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
5765
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LRMR's Valuation (23) in the null industry is somewhat better than the same rating for ABUS (64) in the Biotechnology industry. This means that LRMR’s stock grew somewhat faster than ABUS’s over the last 12 months.

ABUS's Profit vs Risk Rating (64) in the Biotechnology industry is somewhat better than the same rating for LRMR (100) in the null industry. This means that ABUS’s stock grew somewhat faster than LRMR’s over the last 12 months.

ABUS's SMR Rating (98) in the Biotechnology industry is in the same range as LRMR (100) in the null industry. This means that ABUS’s stock grew similarly to LRMR’s over the last 12 months.

ABUS's Price Growth Rating (57) in the Biotechnology industry is in the same range as LRMR (65) in the null industry. This means that ABUS’s stock grew similarly to LRMR’s over the last 12 months.

ABUS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as LRMR (100) in the null industry. This means that ABUS’s stock grew similarly to LRMR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABUSLRMR
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
86%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 30 days ago
80%
Bullish Trend 13 days ago
87%
Declines
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
87%
View a ticker or compare two or three
Ad is loading...
ABUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LRMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MWMZX32.160.37
+1.16%
VanEck Morningstar Wide Moat Z
FFIDX95.801.05
+1.11%
Fidelity
TRSYX15.680.15
+0.97%
T. Rowe Price Small-Cap Index
IHSUX28.430.23
+0.82%
Hartford Small Company R5
FESCX10.24N/A
N/A
First Eagle Small Cap Opportunity I

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with ARRY. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then ARRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
N/A
ARRY - ABUS
43%
Loosely correlated
+5.15%
AXON - ABUS
42%
Loosely correlated
+2.59%
ROIV - ABUS
39%
Loosely correlated
+0.61%
THRD - ABUS
38%
Loosely correlated
-0.37%
VCYT - ABUS
38%
Loosely correlated
+4.66%
More

LRMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with SVRA. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then SVRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LRMR
1D Price
Change %
LRMR100%
+1.13%
SVRA - LRMR
39%
Loosely correlated
+0.31%
ABSI - LRMR
36%
Loosely correlated
+1.88%
IDYA - LRMR
36%
Loosely correlated
+3.31%
TRDA - LRMR
35%
Loosely correlated
+1.85%
BDTX - LRMR
35%
Loosely correlated
+1.60%
More